Multihance

Active Ingredient:: Gadobenate Dimeglumine
Origin:: EU

Multihance (Gadobenate Dimeglumine)

Q: What is Multihance used for?

Multihance is a gadolinium‑based contrast agent used to enhance magnetic resonance imaging of the central nervous system, liver, cardiovascular system, and blood vessels. By improving signal intensity on T1‑weighted images, it helps radiologists detect and characterize lesions more accurately.

Q: How does gadobenate dimeglumine work?

Gadobenate dimeglumine is a paramagnetic chelate that shortens the T1 relaxation time of nearby water protons. After intravenous injection, it distributes in the extracellular space and transiently accumulates in areas with increased vascularity or disrupted barriers, producing brighter signals on T1‑weighted MRI sequences.

Q: What is the usual dose of Multihance?

The specific dose of Multihance is determined by the prescribing physician based on the imaging protocol, patient weight, and renal function. Dosing guidelines are provided in the product label, and the prescriber tailors the amount to achieve optimal image quality while maintaining safety.

Q: Is Multihance safe during pregnancy or breastfeeding?

Safety data for gadobenate dimeglumine in pregnancy are limited, so it should only be used when clearly indicated and the potential benefit outweighs the risk. For breastfeeding mothers, the decision should consider the infant’s exposure; the manufacturer advises consulting a healthcare professional.

Q: How do I order Multihance from GNH India?

To order Multihance, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Q: How does Multihance compare with other gadolinium contrast agents?

Multihance (gadobenate dimeglumine) offers higher relaxivity than many conventional gadolinium agents, providing stronger T1 shortening and potentially allowing lower doses for comparable image quality. It is particularly valued for liver-specific imaging because of partial hepatocyte uptake, distinguishing it from agents without liver‑specific properties.

Q: What are the storage and handling requirements for Multihance?

Multihance should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. If the product reaches room temperature, it may be used within a limited time as indicated in the label, but should be returned to controlled storage promptly.

Q: How is Multihance administered?

Multihance is administered as an intravenous injection, typically through a peripheral or central line. The injection is given as a rapid bolus or a power injector, depending on the imaging protocol, followed by a saline flush to ensure complete delivery of the contrast agent.

Q: What are the most serious risks associated with Multihance?

The most serious risks include anaphylactic reactions, nephrogenic systemic fibrosis (NSF) in patients with severe renal impairment, and rare events such as severe hypotension or cardiac arrest. Prompt recognition and emergency management are essential if any severe reaction occurs.

Q: Who should not receive Multihance?

Multihance should be avoided in patients with known severe renal impairment (eGFR <30 mL/min/1.73 m²) due to the risk of NSF, and in individuals with a documented hypersensitivity to gadobenate dimeglumine or any component of the formulation. Caution is also advised for patients with a history of severe allergic reactions to contrast media.

Gadobenate dimeglumine, the active ingredient in Multihance, is a gadolinium-based contrast agent presented as a 0.5 mmol/mL solution for injection for intravenous use. It enhances magnetic resonance imaging of specific organs and vascular structures in adult patients.

GNH India supplies Multihance as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Bracco Imaging Deutschland Gmbh

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Multihance is used in magnetic resonance imaging procedures to improve visualization of the central nervous system, liver, vascular system, and cardiac structures.

Central nervous system MRI: provides enhanced signal intensity for better lesion detection and anatomical detail.
Liver MRI: improves lesion conspicuity and characterization of hepatic lesions.
Magnetic resonance angiography (MRA): increases vascular contrast for clearer depiction of arteries and veins.
Cardiac MRI: enhances myocardial and blood‑pool visualization for functional and perfusion assessment.

How It Works

Gadobenate dimeglumine is a paramagnetic gadolinium chelate that shortens the T1 relaxation time of nearby water protons. When administered intravenously, it distributes in the extracellular fluid and transiently accumulates in tissues with increased vascularity or disrupted blood‑brain barriers, thereby producing a higher signal intensity on T1‑weighted MRI sequences and improving image contrast.

Side Effects

Adverse reactions may occur following intravenous administration of gadolinium‑based contrast agents.

Common Side Effects

Nausea: mild to moderate feeling of stomach upset.
Headache: transient discomfort after injection.
Injection site discomfort: pain or burning sensation at the cannula site.
Warmth or flushing: sensation of heat spreading through the body.
Metallic taste: brief metallic sensation in the mouth.
Dizziness: light‑headed feeling that usually resolves quickly.

Serious or Rare Side Effects

Anaphylactic reaction: severe allergic response requiring immediate medical intervention.
Nephrogenic systemic fibrosis (NSF): rare fibrotic disorder in patients with severe renal impairment.
Severe hypotension: marked drop in blood pressure shortly after injection.
Cardiac arrest: extremely rare but life‑threatening event.
Acute kidney injury: sudden decline in renal function, especially in at‑risk patients.
Pulmonary edema: accumulation of fluid in the lungs, presenting with shortness of breath.

Precautions & Warnings

Prior to using Multihance, clinicians should assess patient-specific risk factors and follow handling guidelines.

Renal function assessment: evaluate kidney function (eGFR) before administration.
Pregnancy: use only if clearly needed, as safety data are limited.
Breastfeeding: consider potential exposure to the infant and weigh benefits versus risks.
History of allergic reactions: review prior contrast media reactions and be prepared for emergency management.
Concurrent nephrotoxic drugs: monitor renal status when used with agents that may impair kidney function.
Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Gadobenate dimeglumine may interact with other agents that affect renal function or increase gadolinium load.

Major Interactions (Avoid)

Severe renal impairment (eGFR <30 mL/min/1.73 m²): heightened risk of nephrogenic systemic fibrosis; avoid use.
Concurrent administration of other gadolinium‑based agents: cumulative gadolinium exposure may increase toxicity.

Moderate Interactions (Monitor Closely)

Loop diuretics: may alter renal clearance, requiring closer monitoring of kidney function.
Nephrotoxic antibiotics (e.g., aminoglycosides, vancomycin): increase risk of renal injury; assess renal parameters.
ACE inhibitors or ARBs: may affect renal perfusion; monitor for changes in renal function.
High‑dose corticosteroids: potential for altered fluid balance; observe for adverse effects.

Frequently Asked Questions

Multihance is a gadolinium‑based contrast agent used to enhance magnetic resonance imaging of the central nervous system, liver, cardiovascular system, and blood vessels. By improving signal intensity on T1‑weighted images, it helps radiologists detect and characterize lesions more accurately.

Gadobenate dimeglumine is a paramagnetic chelate that shortens the T1 relaxation time of nearby water protons. After intravenous injection, it distributes in the extracellular space and transiently accumulates in areas with increased vascularity or disrupted barriers, producing brighter signals on T1‑weighted MRI sequences.

The specific dose of Multihance is determined by the prescribing physician based on the imaging protocol, patient weight, and renal function. Dosing guidelines are provided in the product label, and the prescriber tailors the amount to achieve optimal image quality while maintaining safety.

Safety data for gadobenate dimeglumine in pregnancy are limited, so it should only be used when clearly indicated and the potential benefit outweighs the risk. For breastfeeding mothers, the decision should consider the infant’s exposure; the manufacturer advises consulting a healthcare professional.

To order Multihance, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Multihance (gadobenate dimeglumine) offers higher relaxivity than many conventional gadolinium agents, providing stronger T1 shortening and potentially allowing lower doses for comparable image quality. It is particularly valued for liver-specific imaging because of partial hepatocyte uptake, distinguishing it from agents without liver‑specific properties.

Multihance should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. If the product reaches room temperature, it may be used within a limited time as indicated in the label, but should be returned to controlled storage promptly.

Multihance is administered as an intravenous injection, typically through a peripheral or central line. The injection is given as a rapid bolus or a power injector, depending on the imaging protocol, followed by a saline flush to ensure complete delivery of the contrast agent.

The most serious risks include anaphylactic reactions, nephrogenic systemic fibrosis (NSF) in patients with severe renal impairment, and rare events such as severe hypotension or cardiac arrest. Prompt recognition and emergency management are essential if any severe reaction occurs.

Multihance should be avoided in patients with known severe renal impairment (eGFR <30 mL/min/1.73 m²) due to the risk of NSF, and in individuals with a documented hypersensitivity to gadobenate dimeglumine or any component of the formulation. Caution is also advised for patients with a history of severe allergic reactions to contrast media.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 17 Sep 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.